Project Grant R01HL174547
Award Date
7/15/24
Completion Date
4/30/28
Dollars Obligated
$1.6M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant, awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), aims to dissect the peripheral mechanisms underlying fentanyl-induced cardiorespiratory depression. The $671,732 award to The Washington University in St. Louis will fund research to: 1) evaluate the use of peripherally-acting mu-opioid receptor (MOR) antagonists to prevent and reverse fentanyl overdoses without withdrawal effects, 2) assess...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on investigating the role of opioid receptor activation in the carotid body to mitigate opioid-induced respiratory depression (OIRD) caused by fentanyl. The $712,167 award to the University of Chicago will be used to test the hypotheses that: A) fentanyl stimulates the carotid body by acting as a partial kappa-opioid receptor...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), seeks to uncover the biological basis for why sleep apnea patients are more sensitive to opioid-induced respiratory depression (OIRD), the primary cause of death due to opioid overdose. The $1,704,286 award to Texas A&M University System Health Science Center aims to investigate how deficient oxytocin neurotransmission contributes to OIRD...
The National Institute on Drug Abuse (NIDA) awarded a $779,969 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Michigan. The grant, with a performance period from September 30, 2024 to July 31, 2029, aims to improve perioperative care for patients with opioid use disorder. The key objectives are to: 1) capture patient-reported pain and opioid use among individuals with opioid use disorder undergoing common surgical procedures,...
This $1,389,597 Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), supports research by the University of Chicago to investigate the physiological and cellular impacts of fentanyl overdose and the reversal of fentanyl-induced cardiorespiratory collapse. The primary objectives are to characterize how fentanyl and the reversal of opioid-induced respiratory depression impact factors such as oxygen consumption,...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
This $701,959 Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), aims to improve perioperative care for patients with opioid tolerance. The key objectives are to: Capture patient-reported opioid use and pain outcomes among opioid-tolerant individuals undergoing common surgical procedures, and develop a clinical care pathway to optimize outcomes across a network of hospitals in Michigan....
This $360,100 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to investigate the role of mu opioid receptors (MORs) and their splice variants in regulating respiratory function and the neonate autoresuscitation reflex. The primary objectives are to: 1) determine how the loss of OPRM1 gene expression modulates the neonatal autoresuscitation reflex and respiratory...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $1,243,350.00 to the University of Nebraska Medical Center (UNMC) to conduct research on the mechanisms underlying sleep disturbances during opioid withdrawal. The primary objectives are to: Determine if and how chronic morphine administration disrupts the neuronal activity and properties of wake-active noradrenergic neurons in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), which is part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc. for a 12-month project. The overarching goal is to design, synthesize, and test non-opioid drug candidates that could help reverse the effects of synthetic opioids like fentanyl. Specific aims include: 1) Designing and characterizing lead compounds and control compounds for receptor binding and ADMET...